Your browser is no longer supported. Please, upgrade your browser.
NVS [NYSE]
Novartis AG
Index- P/E24.65 EPS (ttm)3.52 Insider Own9.30% Shs Outstand2.26B Perf Week-3.00%
Market Cap215.41B Forward P/E12.83 EPS next Y6.76 Insider Trans0.00% Shs Float2.11B Perf Month-9.62%
Income8.07B PEG3.00 EPS next Q1.64 Inst Own10.40% Short Float0.25% Perf Quarter-0.69%
Sales49.90B P/S4.32 EPS this Y14.20% Inst Trans1.92% Short Ratio2.54 Perf Half Y0.30%
Book/sh25.02 P/B3.47 EPS next Y6.04% ROA6.30% Target Price104.50 Perf Year-0.46%
Cash/sh4.65 P/C18.63 EPS next 5Y8.23% ROE15.00% 52W Range69.18 - 98.52 Perf YTD-8.18%
Dividend3.38 P/FCF39.98 EPS past 5Y4.10% ROI8.80% 52W High-11.99% Beta0.57
Dividend %3.90% Quick Ratio0.70 Sales past 5Y-0.20% Gross Margin71.10% 52W Low25.34% ATR1.30
Employees105794 Current Ratio0.90 Sales Q/Q2.50% Oper. Margin20.30% RSI (14)32.14 Volatility0.96% 1.17%
OptionableYes Debt/Eq0.67 EPS Q/Q88.00% Profit Margin16.20% Rel Volume1.03 Prev Close87.43
ShortableYes LT Debt/Eq0.49 EarningsJan 26 BMO Payout87.10% Avg Volume2.04M Price86.71
Recom1.00 SMA20-3.95% SMA50-5.81% SMA200-1.38% Volume2,107,248 Change-0.82%
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Feb-24-21 09:31AM  
Feb-19-21 07:45AM  
Feb-17-21 11:18AM  
07:26AM  
01:15AM  
Feb-16-21 01:23PM  
Feb-12-21 10:06AM  
08:56AM  
Feb-11-21 11:19AM  
07:00AM  
Feb-10-21 01:50PM  
Feb-09-21 10:16AM  
Feb-07-21 10:25AM  
Feb-04-21 06:00PM  
10:01AM  
07:21AM  
Jan-29-21 12:05PM  
10:22AM  
Jan-28-21 04:40PM  
06:36AM  
Jan-27-21 10:48AM  
Jan-26-21 10:01PM  
04:22PM  
09:38AM  
08:07AM  
07:56AM  
07:22AM  
07:00AM  
04:56AM  
02:20AM  
01:14AM  
01:00AM  
Jan-25-21 10:24AM  
Jan-23-21 08:10PM  
Jan-22-21 01:49PM  
Jan-21-21 10:29AM  
07:04AM  
Jan-20-21 12:15PM  
10:30AM  
Jan-15-21 09:11AM  
08:14AM  
Jan-14-21 04:35PM  
03:11PM  
Jan-12-21 04:31PM  
02:58PM  
08:15AM  
Jan-11-21 04:30PM  
Dec-31-20 08:52AM  
Dec-28-20 07:30AM  
07:00AM  
Dec-22-20 09:08AM  
Dec-21-20 10:16AM  
Dec-18-20 07:04PM  
05:08PM  
04:50PM  
07:34AM  
Dec-17-20 12:29PM  
09:25AM  
Dec-16-20 01:31PM  
07:15AM  
Dec-15-20 07:17PM  
10:37AM  
07:27AM  
01:15AM  
Dec-14-20 01:15AM  
Dec-11-20 09:29AM  
Dec-09-20 09:45AM  
09:00AM  
Dec-08-20 04:23PM  
10:00AM  
Dec-05-20 10:00AM  
Dec-04-20 12:30PM  
08:00AM  
Dec-03-20 04:33PM  
04:12AM  
Dec-02-20 04:09PM  
Nov-25-20 09:30AM  
Nov-24-20 08:12AM  
07:13AM  
01:00AM  
Nov-23-20 07:00PM  
Nov-20-20 11:20AM  
10:17AM  
09:44AM  
08:42AM  
07:37AM  
Nov-19-20 04:30PM  
10:00AM  
09:43AM  
01:15AM  
Nov-18-20 01:29AM  
Nov-16-20 01:54PM  
Nov-15-20 06:52AM  
Nov-13-20 10:00AM  
Nov-10-20 05:06PM  
04:46PM  
Nov-06-20 07:47AM  
02:00AM  
01:15AM  
Nov-05-20 04:11PM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 30Buy17.00125,0002,125,0001,181,258Jul 02 04:16 PM